Measurement of glomerular and peritubular capillaritis in kidney transplant biopsy samples identifies allograft dysfunction associated with alloantibodies. Sis et al. show that this technique has a higher sensitivity but lower specificity than the current diagnostic criteria using peritubular capillary C4d deposition, and that capillaritis is an independent predictor of progression to graft failure.
The majority of cases of late renal allograft dysfunction and loss are caused by the presence of donor-specific antibodies (DSAs) to HLA antigens.
1 This complication makes it imperative to develop better methods of diagnosing antibody-mediated rejection at an early stage. A major step forward in this area was the application of a stain developed by Feucht to detect the complement fragment C4d in biopsy samples from patients with transplant glomerulopathy or arterio pathy. The triad of peritubular capillary C4d deposition, transplant glomerulopathy or arteriopathy and presence of DSAs was used to define chronic humoral rejection, which is now officially known in the Banff classification as chronic active antibody-mediated rejection (CAMR).
2 In a paper from 2002, Regele et al. noted that peritubular capillaritis and glomerulitis with mononuclear cells were also strongly associated with C4d-positive CAMR; 3 this finding was confirmed in a later study by Gibson and colleagues. 4 Halloran's group have long associated peritubular capillaritis and glomerulitis with neutrophils with DSA-positive acute rejection, and have been long-time advocates of the importance of DSA. Although detection of C4d has been the cornerstone in the diagnosis of antibody-mediated rejection for over 10 years, it has become clear that some cases of antibody-mediated rejection with DSAs, which are otherwise pathologically similar, do not have detectable C4d in the peritubular capillaries or have only very low levels. These C4d-negative cases can be manifested by peritubular capillaritis and/ or increased endothelial activation. 5, 6 Sis et al. have therefore developed an algorithm to improve diagnostic accuracy in the presence of variable C4d deposition.
7
Sis and colleagues examined 329 biopsy samples from patients with graft dysfunction, and scored glomerulitis, peritubular capillaritis and C4d deposition in peritubular capillaries according to the Banff categories, correlating these results with the presence of DSAs by a single-antigen bead assay at the time of biopsy. 7 C4d was negative or minimally positive (<10% of peri tubular capillaries) in many of the cases with DSA (65%), although the stain remained highly specific (98%) for the presence of DSA. The investigators found that in the first year after transplantation, peritubular capillaritis and glomerulitis were often not associated with DSA (27%), and
Figure 1 | Mechanisms of donor-specific antibody-mediated endothelial injury in renal allografts. Anti-MHC antibodies can cause direct injury to the capillary endothelium, or indirect injury via complement fixation or recruitment of inflammatory cells with Fc receptors. Endothelial injury and cellular recruitment could be important mediators in cases with donor-specific antibodies that lack C4d deposition. Capillaritis has been proposed as a sensitive marker for the presence of donor-specific antibodies and late allograft rejection.
7 Abbreviations: MHC, major histocompatibility complex; NK, natural killer cell; Poly, polymorphonuclear cell. NEWS & VIEWS they recommended C4d staining as the more definitive test for antibody-mediated rejection in the first year after transplantation. After 1 year, however, aggregate capillaritis (both in peritubular capillaries and glomeruli) was more often associated with DSA (79%), although the specificity (90%) was inferior to using C4d staining. The authors developed a decision tree based on these results to predict DSA status. The analysis started by determining whether glomerulitis (at least one glomerulus with inflammatory cells) or peritubular capillaritis (>10% of peritubular capillaries with more than two leukocytes) was present, time post-transplantation (>351 days or >466 days), and finally, whether >10% of peritubular capillaries were C4d-positive. Sis et al. then validated the decision-tree approach and compared it with C4d staining alone for prediction of DSA. The decision tree was more sensitive than was C4d (59% versus 35%, respectively), but was less specific (90% versus 98%, respectively). Taken together, these opposing performance characteristics led to similar accuracy in predicting DSA (80% versus 76%, respectively). Notably, glomerulitis or peritubular capillaritis predicted a worse outcome in patients overall, which correlated directly with more extensive intracapillary inflammation in biopsy samples. Univariate correlation with C4d staining and outcome was not reported, but the authors stated that it had no additional predictive value after cases were sorted by capillaritis.
How will these results inform pathological interpretation of renal biopsy samples? First, they will focus more attention on evaluating peritubular capillaritis and glomerulitis, which is unfortunately a notoriously difficult assignment. Reported interobserver agreement for glomerulitis ranges from poor to moderate, with only moderate interobserver agreement for peritubular capillaritis. 4 This variation is partly due to the difficulty in identifying peritubular capillaries in routine sections and the tedium of counting cells in hundreds of capillaries. Counting cells in glomeruli is easier, but no specific threshold for cell number exists in the Banff classification for a glomerulus affected by glomerulitis. A quantitative immunohistochemical strategy to identify and quantify intra capillary cells from amidst interstitial inflammation could improve the rigor of capillaritis and glomerulitis scoring.
The lack of specificity is the second problem for evaluation of peritubular capillaritis or glomerulitis. Here, defining specific cell ular mediators of CAMR could be useful. Sis and colleagues show increased numbers of intraglomerular CD56 + natural killer (NK) cells in four of six cases of CAMR. Although this sample is hardly large enough to provide convincing results, other data point to a role for NK cells in CAMR, including increased levels of NK-cellspecific transcripts 8 and experimental studies in mice which show that CAMR is dependent on NK cells and not complement fixation.
9 Unfortunately, NK cells are exceedingly difficult to detect in tissue as their phenotype varies with activation (activated NK cells lose CD56 expression) and few markers are specific to NK cells. Nonetheless, using a combination of stains to detect markers of activated NK cells, such as CD16 and transcription factor T-bet, is quite feasible.
The low sensitivity of C4d staining leads Sis et al. to dismiss its value. In our experi ence, however, the sensitivity of C4d staining is much higher, at least 60%. The reasons for this difference are unknown, but could depend on the patient population, the indications for biopsy, the sensitivity of the DSA test and perhaps the sensitivity of the C4d technique itself. We use a triple-layer immuno fluorescence technique, which is regarded as the most sensitive.
We certainly agree that a small number of CAMR cases have little or no detectable C4d, even with the most sensitive techniques. What is the explanation? Negative C4d could be the result of a fluctuation in deposition owing to DSA titer, alterations in endothelial HLA regulation or complement clearance, or an inability of DSA subclass to fix complement. The latter is of particular interest as there is evidence for at least three independent mechanisms of injury in CAMR: first, classic complement fixation, as shown by the beneficial effects of anti-C5 therapy in antibody-mediated rejection in presensitized patients; second, antibody-mediated rejection mediated by NK cells independent of complement, as shown in murine studies with some support from observational studies in humans; and third, endothelial activation by antibody alone, best shown in endothelial cell cultures (Figure 1) . 10 These mechanisms are likely to each have their own pathological signature in the biopsy sample, including C4d deposition, accumulation of NK cells and markers of endothelial activation. Identification of mechanisms of injury in CAMR will also be critical for future therapeutic implications. In addition to strategies to reduce circulating DSAs, complement-dependent CAMR could be addressed with complement inhibitor therapy, whereas Fc-receptor-dependent and NK-cell-dependent CAMR might require cell-directed or Fc inhibitor strategies.
The original formulation of the diagnostic criteria for antibody-mediated rejection had three elements: first, tissue injury such as transplant glomerulopathy and multilamination of peritubular capillary basement membranes; second, evidence that the DSA was interacting with the tissue; and third, demonstration of circulating DSAs. At the time of the publication of these criteria, the best marker of antibody interaction with tissue was C4d deposition in peri tubular capil laries, but there was an expectation that new techniques would be developed. The work of Sis et al. 7 and Loupy et al. 5 argue effectively that the second criteria could be fulfilled by assessing peritubular capillaritis or endothelial gene expression. Adding criteria for antibody interaction with the tissue should be relatively easy once a reliable and efficient methodology is established. 
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HYPERTENSION
RAS blockade, hyperkalemia and AKI-look and you will find
Robert D. Toto
Aliskiren combined with other inhibitors of the renin-angiotensin system increases the risk of hyperkalemia. This risk does not translate into an increased incidence of acute kidney injury, suggest the results of a metaanalysis. However, further research is needed to fully evaluate the safety of combination therapy with aliskiren.
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Orally active renin inhibitors are a potent and relatively new class of antihyper tensive agents and the effect of this class of antihypertensive agents on serum potassium levels has not been fully evaluated. A member of this drug class, aliskiren, was approved for the treatment of hypertension in March 2007. 1 Theoretically, by blocking renin-which is involved in the ratelimiting step in the synthesis of the potent aldo sterone secretagogue angiotensin IIrenin inhibitors might be expected to result in an increased incidence of hyperkalemia in susceptible populations. In a systematic review and meta-analysis, Harel et al. examined the incidence of hyper kalemia, defined as a serum potassium level of >5.5 mmol/l, and acute kidney injury (AKI) among indivi duals treated with aliskiren alone or in combination with either an angiotensin-converting-enzyme (ACE) inhibitor or a type-1 angiotensin II receptor blocker (ARB).
2 Extracellular potassium concentration is maintained within a very narrow range through the orchestrated transport of potassium ions across cell membranes in the kidney and in extrarenal tissues such as striated muscle. Increases in extracellular potassium concentration as a result of exogenous and endogenous potassium loads are rapidly corrected by activation of cellular mechanisms that move potassium into the cell and increase renal potassium excretion, thereby restoring potassium concentration to normal levels. In the kidney, potassium homeo stasis is tightly regulated by the coordinated transport of potassium along the nephron and in particular in the cortical collecting duct where mineralocorticoid hormones act to stimulate secretion of potassium into the tubular lumen. Aldosterone, the major mineralo corticoid hormone in humans, is secreted by the adrenal gland in response to increases in ambient angiotensin II and extra cellular potassium concentration, among other factors. Aldosterone in turn upregulates genes which code for proteins that decelerate the movement of epithelial sodium channels into the apical membrane of the collecting duct, thereby increasing the trans epithelial electrical gradient and facilitating potassium secretion by the ATP-sensitive inward rectifier potassium channel 1 in the luminal membrane.
3 Drugs that block the release of aldosterone or block the mineralo corticoid receptor can interfere with this homeostatic process, inhibit potassium secretion and cause hyperkalemia.
ACE inhibitors, ARBs and renin inhibitors are approved for the treatment of hypertension, and ACE inhibitors and ARBs are also approved for the treatment of heart failure and diabetic nephro pathy. Drugs from each of these classes are capable of causing hyperkalemia by blocking aldosterone secretion from the adrenal gland.
Most individuals treated with drugs from these classes for prolonged periods of time do not develop hyperkalemia because of the remarkable capacity of the kidney to adapt to acute and chronic potassium loads by efficiently excreting potassium. However, patients with chronic kidney disease (CKD), those with heart failure or mineralo corticoid deficiency, and elderly individuals have an impaired capacity for renal potassium excretion and are therefore at increased risk of developing hyperkalemia when treated with any of these classes of antihypertensive agents.
In patients with CKD or heart failure, as well as patients with other conditions such as renal artery stenosis and volume depletion, a compensatory (adaptive) increase in efferent, relative to afferent, arteriolar resistance occurs, which serves to increase or maintain single nephron glomerular filtration rate (GFR) in patients with CKD and heart failure, respectively.
4 Under these circumstances, blockade of angiotensin II production or action interferes with this compensatory response, resulting in a decrease in glomerular capillary pressure and, consequently, a decrease in GFR. Such decreases in GFR are manifested by an increase in serum creatinine levels. Treatment of patients with failing kidneys or heart failure with ACE inhibitors, ARBs or renin inhibitors might therefore not only cause hyperkalemia but can also cause AKI. Long-term administration of combinations of drugs that block the renin-angiotensinaldosterone system is known to increase the incidence of hyperkalemia and AKI. [5] [6] [7] [8] [9] It is important to note, however, that in most cases both of these adverse effects are reversible with discontinuation of the drug.
In their meta-analysis, Harel et al. included data from clinical trials in patients with CKD, heart disease, diabetes mellitus and hypertension (without CKD or heart Getty '' ...physicians should take caution in combining aliskiren with an ACE inhibitor or an ARB... '' 
